Roche: FDA accepts application for new lung cancer treatment
(CercleFinance.com) - The FDA has accepted Roche's application for its immunotherapy Tecentriq plus chemotherapy for initial treatment of metastatic non-squamous non-small cell lung cancer, the Swiss drugmaker said on Thursday.
The US Food and Drug Administration has accepted the company's supplemental biologics license application (sBLA) for Tecentriq, in combination with Abraxane and carboplatin, for the first-line treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
The FDA is expected to make a decision on approval by 2 September, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration has accepted the company's supplemental biologics license application (sBLA) for Tecentriq, in combination with Abraxane and carboplatin, for the first-line treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
The FDA is expected to make a decision on approval by 2 September, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.